ES2181677T3 - Metodo y composiciones utiles en la reprogramacion celular. - Google Patents

Metodo y composiciones utiles en la reprogramacion celular.

Info

Publication number
ES2181677T3
ES2181677T3 ES92918753T ES92918753T ES2181677T3 ES 2181677 T3 ES2181677 T3 ES 2181677T3 ES 92918753 T ES92918753 T ES 92918753T ES 92918753 T ES92918753 T ES 92918753T ES 2181677 T3 ES2181677 T3 ES 2181677T3
Authority
ES
Spain
Prior art keywords
programming
aberrant
individual
transcriptional regulator
reprogramation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92918753T
Other languages
English (en)
Inventor
Larry J Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nebraska
Original Assignee
University of Nebraska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Nebraska filed Critical University of Nebraska
Application granted granted Critical
Publication of ES2181677T3 publication Critical patent/ES2181677T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

EL PRESENTE INVENTO PROPORCIONA METODOS Y COMPOSICIONES UTILES EN EL TRATAMIENTO DE CIERTA ENFERMEDADES AQUI LLAMADAS "ENFERMEDADES DE PROGRAMACION ANORMAL", INCLUYENDO EL CANCER Y EL AIDS. DE ACUERDO CON UN ASPECTO DEL INVENTO, HAY PREVISTO UN METODO PARA EL TRATAMIENTO DE UN INDIVIDUO QUE TENGA UNA ENFERMEDAD DE PROGRAMACION ANORMAL CONSISTENTE EN LA ADMINISTRACION A DICHO INDIVIDUO DE UNA CANTIDAD EFECTIVA DE UNA COMPOSICION SELECCIONADA DE UN GRUPO QUE CONSISTE EN UN VECTOR DE EXPRESION, UN OLIGODEOXINUCLEOTIDO DOBLEMENTE TRENZADO, Y UN OLIGODEOXINUCLEOTIDO INVERSO; DICHA COMPOSICION ES CAPAZ DE REGULAR LA PRESENCIA DE UN REGULADOR TRANSCRIPCIONAL, ESTANDO PRESENTADO DICHO REGULADOR TRANSCRIPCIONAL POR LAS CELULAS DE PROGRAMACION ANORMAL Y ADEMAS CARACTERIZADO POR PRESENTAR UN CAMBIO UTIL TERAPEUTICAMENTE EN DICHO COMPORTAMIENTO DE LAS CELULAS EN EL TEST DE REPROGRAMACION. EN UNA VERSION INDEPENDIENTE SE PREVEN OLIGODEOXINUCLEOTIDOS INVERSOS.
ES92918753T 1991-08-23 1992-08-24 Metodo y composiciones utiles en la reprogramacion celular. Expired - Lifetime ES2181677T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74899791A 1991-08-23 1991-08-23

Publications (1)

Publication Number Publication Date
ES2181677T3 true ES2181677T3 (es) 2003-03-01

Family

ID=25011796

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92918753T Expired - Lifetime ES2181677T3 (es) 1991-08-23 1992-08-24 Metodo y composiciones utiles en la reprogramacion celular.

Country Status (10)

Country Link
US (1) US5654415A (es)
EP (3) EP0605466B1 (es)
JP (2) JP4111463B2 (es)
AT (1) ATE221913T1 (es)
AU (1) AU2499892A (es)
CA (1) CA2116327C (es)
DE (1) DE69232722T2 (es)
DK (1) DK0605466T3 (es)
ES (1) ES2181677T3 (es)
WO (1) WO1993003770A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2307293T3 (es) * 1993-10-29 2008-11-16 The Brigham And Women's Hospital, Inc. Utilizacion terapeutica de señuelos de elementos en cis in vivo.
DE19711266C2 (de) * 1997-03-05 1999-06-17 Hepavec Ag Fuer Gentherapie Neue humane Leber-Zellinie
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
US7166712B2 (en) * 2000-07-12 2007-01-23 Philadelphia, Health And Education Corporation Mammalian MDM2 binding proteins and uses thereof
EP1554576B9 (en) 2001-12-03 2008-08-20 Amgen Fremont Inc. Identification of high affinity molecules by limited dilution screening
AU2002353017A1 (en) * 2001-12-03 2003-06-17 Abgenix, Inc. Discovery of therapeutic products
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
WO2009045145A1 (en) * 2007-10-05 2009-04-09 Index Pharmaceuticals Ab Novel compounds for the treatment or alleviation of edema, and methods for their use
US20120156138A1 (en) * 2009-04-14 2012-06-21 Smith Larry J Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming
CA2762369C (en) 2009-05-18 2021-12-28 Joseph Collard Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
EP3760208B1 (en) 2014-06-25 2024-05-29 The General Hospital Corporation Targeting human satellite ii (hsatii)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
JPH04504173A (ja) * 1989-03-06 1992-07-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫吸着剤のアッセイおよび処置
AU5931290A (en) * 1989-06-20 1991-01-08 Meiogenics, Inc. Nuclease resistant, single-stranded, non-naturally occurring nucleic acid molecules
IE20010427A1 (en) * 1990-04-10 2003-03-05 Canji Inc Gene therapy for cell proliferative diseases

Also Published As

Publication number Publication date
JPH07508399A (ja) 1995-09-21
EP0605466B1 (en) 2002-08-07
WO1993003770A1 (en) 1993-03-04
AU2499892A (en) 1993-03-16
EP0605466A1 (en) 1994-07-13
EP2119784A2 (en) 2009-11-18
US5654415A (en) 1997-08-05
DE69232722D1 (de) 2002-09-12
CA2116327C (en) 2009-11-17
JP2005320337A (ja) 2005-11-17
DK0605466T3 (da) 2002-12-09
CA2116327A1 (en) 1993-03-04
EP1271146A1 (en) 2003-01-02
JP4111463B2 (ja) 2008-07-02
EP2119784A3 (en) 2010-07-07
EP0605466A4 (en) 1995-11-22
DE69232722T2 (de) 2002-12-05
ATE221913T1 (de) 2002-08-15

Similar Documents

Publication Publication Date Title
ES2181677T3 (es) Metodo y composiciones utiles en la reprogramacion celular.
BR9908967A (pt) Processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula, tecido ou órgão e para conferir resistência ou imunidade a um patógeno viral sobre uma célula, tecido, órgão ou organismo inteiro, gene sintético capaz de reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo de uma célula, tecido, órgão ou organismo inteiro, construção de gene, uso da mesma, e, célula, tecido, órgão ou organismo inteiro
NO981528L (no) Substituerte imidazoler med antikreft- og cytokininhibitoraktivitet
ATE223215T1 (de) Inhibitoren der fettsäuresynthese als antimikrobielle mittel
FR2587028B1 (fr) Nouveau derive d'azole, procede de fabrication de ce derive, et composition a usage agricole et horticole contenant ce derive comme agent actif
DE69123981D1 (de) Nützliche retrovirale vektoren für die gentherapie
DE69425901D1 (de) Vesikel mit gesteuerter wirkstofffreisetzung
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
MX9602806A (es) Derivados del 1,2,4-oxadiazol y su uso como parasiticidas para animales.
Hardham et al. Reprogramming of cells following wounding in pea (Pisum sativum L.) roots. I. Cell division and differentiation of new vascular elements
Ananiev et al. Localization of RNA synthesis sites in the 1B-3C region of the Drosophila melanogaster X chromosome
Mukherjee et al. 3H-uridine incorporation in the puff 93D and in chromocentric heterochromatin of heat shocked salivary glands of Drosophila melanogaster
DE69508255D1 (de) Dinukleosid-5',5'- pyrophosphate
Gustafsson Observations on the histogenesis of nervous tissue in Diphyllobothrium dendriticum Nitzsch, 1824 (Cestoda, Pseudophyllidea)
ATE295367T1 (de) Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthält
Kanungo et al. Phosphorylation of chromosomal proteins as a function of age and its modulation by calcium
DE69132050D1 (de) Zusammensetzungen von wachstumsfaktoren, herstellung und verwendung
DE69312320D1 (de) Den kalzium kanal blokierende polypeptide aus filistata hibernalis.
ATE366818T1 (de) Hirse-spezifische verzwergungsgene und verfahren ihrer anwendung
EP0777730A4 (en) DNA VECTOR FOR BONE-SPECIFIC GENE EXPRESSION
ES2073919T3 (es) Derivados de piperidina 1,3,4-trisubstituidos, su obtencion y empleo.
SU810177A1 (ru) Способ выкормки тутового шелкопр да
AP2000001974A0 (en) Human BMP-4 promoter and method for exploring bone related substance using the same.
IT1199960B (it) Agenti stimolanti la crescita dei capelli e loro impiego
Ryabchikova et al. Parietal cell ultrastructure in relation to location along the fundic gland